21 September 2021 - - Bryan Giraudo has been appointed chief operating officer at US-based clinical-stage biopharmaceutical company Gossamer Bio, Inc. (NASDAQ: GOSS) in addition to his continued role as chief financial officer, the company said.

Giraudo joined Gossamer in May 2018 as its chief financial officer.

Prior to joining Gossamer Bio, Giraudo was a Senior Managing director at Leerink Partners, now known as SVB Leerink, from 2009 to April 2018.

Before joining Leerink, Giraudo was a managing director in Merrill Lynch's Global Healthcare Investment Banking Group.

Gossamer Bio is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology.